Responsible Use of Opioids

For many years, Purdue has been an industry leader in the fight against opioid abuse and diversion. We are also committed to supporting healthcare professionals on the responsible use of our products.

For information on appropriate use and prescribing of opioid analgesics as well as the risks of opioids, prescription drug abuse, prescription drug monitoring programs, and the extended-release and long-acting (ER/LA) opioid analgesics Risk Evaluation and Mitigation Strategy (REMS), please visit Ask Purdue Medical.

ER/LA Opioid Analgesics REMS

The U.S. Food and Drug Administration (FDA) has mandated that extended-release and long-acting (ER/LA) opioid analgesics have a Risk Evaluation and Mitigation Strategy (REMS) to help ensure that the benefits of the drug outweigh its risks. Learn more about REMS for ER/LA opioid analgesics.

Opioids With Abuse-Deterrent Properties

Purdue was the first company to introduce opioid pain medications with abuse-deterrent properties and labeling claims through development of novel formulations and abuse-deterrence studies.

Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System

For many years, Purdue has dedicated vast resources to combating drug abuse from a range of approaches. The RADARS System, just one example, was developed by Purdue in 2001 to collect and analyze data on drug abuse, diversion, and addiction.

In 2006, Purdue transferred ownership to the Denver Health and Hospital Authority (DHHA) to facilitate access to RADARS surveillance data by pharmaceutical firms and government agencies.

Today, the RADARS System is an independent, non-profit operation of the Rocky Mountain Poison and Drug Center (RMPDC), a division of DHHA.

Radars System